pomalidomide has been researched along with Granulocytic Leukemia, Chronic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Wahab, O; Barbui, T; Barosi, G; Bernard, OA; Bhalla, K; Cazzola, M; Crispino, JD; Finazzi, G; Gisslinger, H; Gotlib, J; Guglielmelli, P; Gupta, V; Hoffman, R; Kiladjian, JJ; Kralovics, R; Mughal, T; Noel, P; Odenike, O; Pardanani, A; Tefferi, A; Thiele, J; Van Etten, RA; Vannucchi, AM | 1 |
1 other study(ies) available for pomalidomide and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Topics: Clinical Trials as Topic; Disease Progression; DNA Methylation; DNA, Neoplasm; Drugs, Investigational; Genes, Neoplasm; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Myeloproliferative Disorders; Neoplasm Proteins; Polyethylene Glycols; Prognosis; Recombinant Proteins; Thalidomide; Treatment Outcome | 2012 |